MarketInOut Stock Screener Log In | Sign Up
 

Liminatus Pharma Inc Cl A

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Liminatus Pharma Inc Cl A stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4.33 mln
Float0.78 mln
Earnings Date10/06/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

11 / 100
Significantly lagging

Debt / Equity

4.80
Highly leveraged

ROE

444
Extraordinary

ROA

-629
Deeply negative

Business Description

Liminatus Pharma is a California-based drug development company focused on finding new ways to treat cancer. Founded in 2018, the company is working on an antibody treatment designed to help the body's own immune system recognize and attack tumor cells more effectively. Unlike some similar approaches, their lead treatment is engineered to avoid damaging red blood cells, which has been a common problem in this area of research.

Key Fundamentals

EPS-23.50
ROE444
ROIC-197
ROA-629
Interest Cover-53.78
EBITDA, mln-12.45
EV / EBITDA-0.21
EV / EBIT-0.21

Quote Details

Last 2.94
Change -0.17 (-5.47%)
Open 3.10
Volume 19,991
Turnover 58,774
Average Volume 26,316

Financial Ratios

Leverage Ratio11.32
Current Ratio1.12
Price / Book13.93
Price / Tangible Book13.93
Debt / Equity4.80

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio1.62
Short % of Float4.12

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -3.29% 21 / 100   
1 Month -29.67% 12 / 100   
2 Months -48.51% 9 / 100   
6 Months -70.33% 6 / 100   
1 Year -94.97% 3 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog